Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CRNX |
---|---|---|
09:32 ET | 12249 | 45.885 |
09:34 ET | 7431 | 46.07 |
09:36 ET | 6040 | 46.94 |
09:38 ET | 2138 | 46.5 |
09:39 ET | 200 | 46.5 |
09:41 ET | 1800 | 46.42 |
09:43 ET | 1400 | 46.4 |
09:45 ET | 800 | 46.44 |
09:50 ET | 300 | 46.285 |
09:52 ET | 400 | 46.41 |
09:54 ET | 1281 | 46.435 |
09:56 ET | 508 | 46.6 |
09:57 ET | 1322 | 46.85 |
09:59 ET | 3468 | 46.97 |
10:01 ET | 1304 | 46.94 |
10:03 ET | 2484 | 46.825 |
10:06 ET | 10936 | 46.76 |
10:08 ET | 1403 | 46.62 |
10:10 ET | 3903 | 46.5761 |
10:12 ET | 650 | 46.58 |
10:14 ET | 3714 | 46.6399 |
10:15 ET | 800 | 46.41 |
10:17 ET | 900 | 46.55 |
10:19 ET | 2154 | 46.605 |
10:21 ET | 200 | 46.485 |
10:24 ET | 9097 | 46.63 |
10:26 ET | 1193 | 46.63 |
10:28 ET | 1200 | 46.735 |
10:30 ET | 7292 | 46.94 |
10:32 ET | 1847 | 46.66 |
10:33 ET | 1158 | 46.67 |
10:35 ET | 1200 | 46.82 |
10:37 ET | 1534 | 46.84 |
10:39 ET | 1300 | 46.89 |
10:42 ET | 1600 | 46.845 |
10:44 ET | 200 | 46.85 |
10:46 ET | 800 | 46.535 |
10:48 ET | 1100 | 46.69 |
10:50 ET | 2180 | 46.52 |
10:51 ET | 700 | 46.56 |
10:53 ET | 700 | 46.54 |
10:55 ET | 708 | 46.62 |
10:57 ET | 6769 | 46.53 |
11:00 ET | 2907 | 46.685 |
11:02 ET | 556 | 46.81 |
11:04 ET | 200 | 46.8 |
11:06 ET | 6950 | 46.665 |
11:08 ET | 300 | 46.47 |
11:09 ET | 300 | 46.46 |
11:11 ET | 1800 | 46.55 |
11:13 ET | 100 | 46.52 |
11:15 ET | 1100 | 46.57 |
11:18 ET | 1761 | 46.54 |
11:20 ET | 800 | 46.47 |
11:22 ET | 400 | 46.56 |
11:24 ET | 300 | 46.56 |
11:26 ET | 1735 | 46.54 |
11:27 ET | 4000 | 46.54 |
11:29 ET | 714 | 46.59 |
11:31 ET | 100 | 46.58 |
11:33 ET | 100 | 46.58 |
11:36 ET | 700 | 46.505 |
11:38 ET | 200 | 46.5 |
11:40 ET | 400 | 46.475 |
11:42 ET | 100 | 46.53 |
11:44 ET | 1400 | 46.4 |
11:45 ET | 600 | 46.48 |
11:47 ET | 1183 | 46.39 |
11:49 ET | 1000 | 46.41 |
11:51 ET | 200 | 46.38 |
11:54 ET | 600 | 46.35 |
11:56 ET | 1389 | 46.37 |
11:58 ET | 200 | 46.35 |
12:00 ET | 200 | 46.39 |
12:02 ET | 2050 | 46.2862 |
12:03 ET | 1484 | 46.25 |
12:05 ET | 3306 | 46.285 |
12:07 ET | 400 | 46.26 |
12:09 ET | 34618 | 46.21 |
12:12 ET | 1059 | 46.2 |
12:14 ET | 2400 | 46.135 |
12:16 ET | 960 | 46.15 |
12:18 ET | 11288 | 46.25 |
12:20 ET | 8167 | 46.06 |
12:21 ET | 135 | 46.055 |
12:23 ET | 3162 | 46.25 |
12:25 ET | 13314 | 46.2775 |
12:27 ET | 6880 | 46.17 |
12:30 ET | 200 | 46.04 |
12:32 ET | 100 | 46.105 |
12:34 ET | 2501 | 45.945 |
12:36 ET | 200 | 45.77 |
12:38 ET | 3548 | 45.97 |
12:39 ET | 226 | 45.955 |
12:41 ET | 404 | 45.99 |
12:43 ET | 1500 | 45.99 |
12:45 ET | 400 | 46.02 |
12:48 ET | 1717 | 46.04 |
12:50 ET | 1800 | 45.94 |
12:52 ET | 800 | 45.9 |
12:54 ET | 1817 | 45.86 |
12:56 ET | 100 | 45.91 |
12:57 ET | 1512 | 45.87 |
12:59 ET | 719 | 45.8 |
01:01 ET | 942 | 45.91 |
01:03 ET | 500 | 45.9 |
01:06 ET | 3159 | 45.855 |
01:08 ET | 700 | 45.92 |
01:10 ET | 1481 | 46.12 |
01:12 ET | 1436 | 46.19 |
01:14 ET | 6758 | 46.25 |
01:15 ET | 1500 | 46.14 |
01:17 ET | 1515 | 46.21 |
01:19 ET | 1700 | 46.2 |
01:21 ET | 2390 | 46.025 |
01:24 ET | 1300 | 45.99 |
01:26 ET | 400 | 45.955 |
01:28 ET | 3177 | 45.87 |
01:30 ET | 200 | 45.885 |
01:32 ET | 1038 | 45.81 |
01:33 ET | 1643 | 45.72 |
01:35 ET | 1017 | 45.735 |
01:37 ET | 800 | 45.79 |
01:39 ET | 1400 | 45.81 |
01:42 ET | 4808 | 45.77 |
01:44 ET | 498 | 45.69 |
01:46 ET | 4210 | 45.54 |
01:48 ET | 5296 | 45.56 |
01:50 ET | 1503 | 45.51 |
01:51 ET | 2465 | 45.465 |
01:53 ET | 200 | 45.47 |
01:55 ET | 3012 | 45.495 |
01:57 ET | 2678 | 45.66 |
02:00 ET | 3934 | 45.5 |
02:02 ET | 1500 | 45.48 |
02:04 ET | 2492 | 45.48 |
02:06 ET | 2300 | 45.49 |
02:08 ET | 22030 | 45.505 |
02:09 ET | 1600 | 45.5 |
02:11 ET | 772 | 45.49 |
02:13 ET | 900 | 45.4 |
02:15 ET | 2858 | 45.48 |
02:18 ET | 26979 | 45.87 |
02:20 ET | 400 | 45.95 |
02:22 ET | 1750 | 46.035 |
02:24 ET | 2715 | 46 |
02:26 ET | 1980 | 45.95 |
02:27 ET | 1400 | 45.84 |
02:29 ET | 1972 | 45.92 |
02:31 ET | 3135 | 45.86 |
02:33 ET | 1116 | 45.87 |
02:36 ET | 1500 | 45.97 |
02:38 ET | 1440 | 46.01 |
02:40 ET | 1895 | 46.015 |
02:42 ET | 1900 | 45.96 |
02:44 ET | 2158 | 45.77 |
02:45 ET | 1950 | 45.855 |
02:47 ET | 1170 | 45.84 |
02:49 ET | 964 | 45.805 |
02:51 ET | 1300 | 45.815 |
02:54 ET | 3099 | 45.765 |
02:56 ET | 600 | 45.72 |
02:58 ET | 2992 | 45.74 |
03:00 ET | 4100 | 45.58 |
03:02 ET | 2962 | 45.535 |
03:03 ET | 1901 | 45.52 |
03:05 ET | 3926 | 45.5 |
03:07 ET | 2149 | 45.4269 |
03:09 ET | 500 | 45.4 |
03:12 ET | 4017 | 45.365 |
03:14 ET | 3100 | 45.25 |
03:16 ET | 5400 | 45.24 |
03:18 ET | 7004 | 45.265 |
03:20 ET | 3585 | 45.385 |
03:21 ET | 3419 | 45.45 |
03:23 ET | 4246 | 45.35 |
03:25 ET | 922 | 45.31 |
03:27 ET | 3600 | 45.465 |
03:30 ET | 3934 | 45.51 |
03:32 ET | 1646 | 45.48 |
03:34 ET | 3200 | 45.555 |
03:36 ET | 8996 | 45.67 |
03:38 ET | 24575 | 45.72 |
03:39 ET | 6967 | 45.69 |
03:41 ET | 4535 | 45.71 |
03:43 ET | 3111 | 45.79 |
03:45 ET | 17371 | 45.86 |
03:48 ET | 13991 | 45.845 |
03:50 ET | 5041 | 45.835 |
03:52 ET | 22555 | 45.85 |
03:54 ET | 13076 | 45.83 |
03:56 ET | 25393 | 45.595 |
03:57 ET | 23679 | 45.55 |
03:59 ET | 37273 | 45.535 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Crinetics Pharmaceuticals Inc | 3.6B | -12.1x | --- |
Dyne Therapeutics Inc | 3.5B | -8.8x | --- |
Merus NV | 3.7B | -19.5x | --- |
Immunovant Inc | 4.0B | -14.1x | --- |
Biohaven Ltd | 3.1B | -5.0x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.6B |
---|---|
Revenue (TTM) | $2.0M |
Shares Outstanding | 78.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.68 |
EPS | $-3.77 |
Book Value | $7.91 |
P/E Ratio | -12.1x |
Price/Sales (TTM) | 1,840.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -12,571.38% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.